Radient Pharmaceuticals Announces FY2011 Conference & Events Schedule

November 3, 2010 |

5 min read

TUSTIN, CA--(Marketwire - November 03, 2010) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today plans to participate in nine key industry events throughout fiscal year 2011 as part of the Company’s continued dedication to the oncology and in vitro diagnostics (IVD) sectors.

These established industry conferences provide a tremendous opportunity for RPC to showcase RPC’s IVD products, learn and discuss current developments in oncology and IVD technology, and pursue potential strategic partnerships. Participation in events will afford Radient the opportunity to showcase the Company’s Onko-Sure® IVD cancer test, while presenting results of RPC’s ongoing clinical studies to domestic and global audiences. RPC will sponsor a booth in many of these events and provide informative literature detailing ongoing clinical studies. The events in chronological order are as follows:

---------------------------------------------------------------------------- Date Event Location ---------------------------------------------------------------------------- February 24-26 ESMO European Multidisciplinary Lugano, Switzerland Conference in Thoracic Oncology March 2-5 Annual Cancer Symposium of the San Antonio, TX Society of Surgical Oncology April 2-6 AACR 102nd American Association for Orlando, FL Cancer Research May 6-10 SSAT 52nd Annual Meeting of the Chicago, IL Society for Surgery of Alimentary Tract May 14-18 ASCRS American Society of Colon and Vancouver, BC Rectal Surgeons Annual Meeting June 3-7 ASCO American Society of Clinical Chicago, IL Oncologists July 3-7 IASLC 14th World Conference on Amsterdam, The Netherlands Lung Cancer TBD TOC 12th Annual Thoracic Oncology San Francisco, CA Conference TBD 7th Annual New York Lung Cancer NYC Symposium ----------------------------------------------------------------------------

Douglas MacLellan, Executive Chairman and CEO of RPC, commented, “The global in vitro diagnostics (IVD) cancer market is expected to maintain robust growth over the next five years and we are committed to participating in key industry events to stay abreast of the latest industry dynamics and market intelligence and promote RPC and our Onko-Sure® IVD cancer test kits globally. Attendance and participation by way of executive presentations and booth exhibiting complements RPC’s broad international sales and marketing strategy and further demonstrates our commitment to drive increased market awareness, understanding, and adoption of our core products.”

RPC’s Onko-Sure® IVD cancer test, a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer.

For more information, or to schedule time with an RPC representative at any of the above events, contact Radient Pharmaceutical International Sales at sales@radient-pharma.com. For additional information on Radient Pharmaceuticals and its portfolio of IVD cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

About Provista Diagnostics Inc.
Provista Diagnostics is a healthcare and biotechnology development company located in
Phoenix, AZ, that provides innovative tests for early disease detection to medical professionals and patients. For more information, visit the company’s Web site at www.ProvistaLS.com or call 1.602.224.5500.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.